Related Experiment Video

Updated: Sep 21, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Short-term gluten challenge in children with coeliac disease does not impair spontaneous growth hormone secretion

Ulf H G Jansson1, Bengt Kristiansson, Kerstin Albertsson-Wikland

  • 1Göteborg Pediatric Growth Research Center, Department of Pediatrics, The Sahlgrenska Academy at Göteborg University, Sweden. ulf.jansson@ltjkpg.se

Journal of Pediatric Endocrinology & Metabolism : JPEM
|July 26, 2003
PubMed

Insights

Growth in children with celiac disease is not due to impaired growth hormone (GH) secretion. This study found no significant changes in GH secretion during a gluten challenge, suggesting other factors may affect growth.

Area of Science:

  • Pediatric Endocrinology
  • Gastroenterology
  • Growth Disorders

Background:

  • Growth retardation in children with celiac disease is often linked to impaired growth hormone (GH) secretion.
  • Previous studies observed reduced GH secretion in stimulation tests for celiac disease patients.

Purpose of the Study:

  • To investigate spontaneous GH secretion changes during a standardized gluten challenge in children with suspected celiac disease.
  • To determine if gluten exposure affects 24-hour GH secretion patterns.

Main Methods:

  • Twelve children with suspected celiac disease underwent a 5-6 week gluten challenge.
  • Repeated 24-hour GH sampling was performed before and after the challenge.
  • GH levels were analyzed using the PULSAR computer program to assess secretion parameters.

Main Results:

  • No significant differences were observed in GH peak, baseline GH, GH peak number, or mean GH concentration.
  • A slight increase in GH secretion rate (GHt) was noted, but not significantly correlated with IGF-I changes.
  • The 24-hour GH secretion profile characteristics did not significantly change post-gluten challenge.

Conclusions:

  • The study found no evidence of impaired spontaneous GH secretion in children with celiac disease during a gluten challenge.
  • Growth retardation in celiac disease may not be primarily due to altered GH secretion.
  • Altered peripheral sensitivity to GH is proposed as a potential alternative cause for growth issues in celiac disease.
Abstract

More Related Videos

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...